Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1200 participants.
Also called NCT07175428
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 1,200 participants
- Sponsor
- Registry
-
NCT07175428
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Brazil, Canada
- Registry status
- Recruiting
Technical summary
Registry record NCT07175428. Randomized; single masking; primary purpose prevention. Start 2025-10-20 (actual); primary completion 2027-02-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
- Acronym
- ROXI-ATLAS
- Condition
- Atrial Fibrillation (AF)
- Intervention (Drug)
- REGN7508
- Intervention (Drug)
- REGN9933
- Intervention (Drug)
- Apixaban
- Lead sponsor
- Regeneron Pharmaceuticals
Record details
- Record id
cardio:ct-nct07175428- Content hash
682c2935bf6677f4635d546d4449987b447107b1ae6e0bc0881e030fcb78c66b